The performance ofa fluorescence imaging device was compared with conventional white-light bronchoscopy in 100 patients with lung cancer, 46 patients with resected stage non-small cell lung cancer, l0 patients with head and neck cancer, and 67 volunteers who had smoked at least pack of cigarettes per day for 25 years or more. Using differences in tissue autofluorescence btween premalignant, malignant, and normal tissues, fluorescence bronchoscopy was found to detect significantly more areas with moderate/severe dysplasia or carcinoma in situ than conventional white-light bronchoscopy with a similar specificity. Multiple foci of dysplasia or cancer were found in 13-24% of these individuals. Fluorescence bronchoscopy may be an important adjunct to conventional bronchoscopic examination to improve our ability to detect and localize premalignant and early lung cancer lesions.
INTRODUCTION
The best results of photodynamic therapy (PDT) for lung cancer are seen in patients with carcinoma in situ or microinvasive cancers. Complete eradication of these early lung cancer lesions without loss of normal lung tissue or lung function capacity can be seen in over 90% of these patients (Hayata et al., 1993; Furuse et al., 1993; Edell and Cortese, 1992) . When precancerous lesions are found, chemoprevention agents, such as 13-cis-retinoic acid or Retinol can be used to regress the lesions (Lippman et al., 1990 , Pastorino et al., 1993 . Despite the availability of these treatment modalities, very few patients benefit from them because dysplasia and early lung cancer lesions are very difficult to detect and localize with conventional white-light bronchoscopic examination. In a study by Woolner and coworkers (Woolner et al., 1984) , only 29% of carcinoma in situ (CIS) were visible to an experienced endoscopist. Even for pathologists who had the opportunity to carefully examine the resected specimens, they were able to visualize the site of the CIS lesions in only 41% of the cases (Woolner et al., 1984) . In an attempt to overcome this problem, a lung imaging fluorescence endoscopic (LIFE) device was developed to detect precancerous and CIS lesions using differences in tissue autofluorescence between normal and abnormal tissues Lain et al., 1993; Palcic et al., 1991; Lain and Palcic, 1993) .
The objective of this study was to determine if fluorescence bronchoscopy using the LIFE device can improve the ability of conventional white-light bronchoscopy to detect bronchial dysplasia and CIS.
MATERIALS AND METHODS

Life
LIFE is comprised of a helium-cadmium laser as a light source (442 nm), two image-intensified CCD cameras with green (520 nm) and red (>630 nm) filters, respectively, acomputerwith an imaging board, and a colorvideo monitor (Lam and Palcic, 1993 (Hayata et al., 1993; Nagamoto et al., 1986) . The nodular or polypoid type of early lung cancer usually presents as an area of protrusion. Nodular lesions are easier to detect because they are elevated from the adjacent normal mucosa. Lesions as small as 0.2 cm can be detected by white-light bronchoscopy (Hayata et al., 1993; Nagamoto et al., 1986) . The bronchoscopic appearance of bronchial dysplasia has not been carefully studied. In this study, the dysplastic lesions thatwere visible on whitelight bronchoscopy presented as focal thickening of the mucosal fold or bifurcation. Overall, 40% of the dysplastic lesions or CIS were visible by white-light examination. Since the bronchoscope only serves as a means to examine the surface of a body cavity, it is unlikely that further advances in white-lightbronchoscopy can improve our ability to detect pre-cancerous lesions or early cancer. Our study suggests that instead of making use of the refleeted/scattered light, one can use light induced tissue autofluorescence to improve the detection rate of these early lung cancer lesions by more than two times with a similar specificity.
The results in this study are similar to ourprevious study involving 94 subjects where we observed a sensitivity of 72.5% for fluorescence bronchoscopy in detecting moderate/severe dysplasia and carcinoma in situ with a specificit of 94%. Using white light bronchoscopy, the sensitivity was 48.4% with the same specificity . In both studies, false-positives were due to inflammatio in the submucosa or squamous metaplasia resulting in swelling orthickening ofthe mucosa. The reason for the false-negative sites (3/35 CIS lesions) was not clear. All three tumors regressed spontaneously on follow-up. It is possible that in situ carcinomas with nonaggressive biological behaviorhave differentreflectance and fluorescence properties. The concept offluorescence detection has intrigued the minds of many since the beginning of the twentieth century. In 1924, Policard observed that in an experimental model of sarcoma, the tumor tissue fluoresced red upon illumination by Wood's light (Policard, 1924) . In 1933, Sutro and Burman observed that when surgically excised breast tissue was exposed to Wood's light, normal breast tissue fluoresced green, while breast cancer tissues fluoresced purple (Sutro ar. Burman, 1993) . These observations were confirmed by others in cancer of the skin and mouth in addition to breast cancer (Ronchese, 1954) . Red fluorescence was found to be associated with advanced cancers only (Ronchese, 1954 (Auerbach et al., 1961) . In the same study, in smokers who died of non-lung cancer causes, CIS was found in 4.3% of those who smoked 1-2 packs per day and 11.4% of those who smoked more than 2 packs a day (Auerbach et al., 1961) . In patients resected stage I lung cancer, second primary tumors occur in 10-20% of cases (Pastorino et al., 1993; Thomas et al., 1990; Cortese, et al., 1983) . The prevalence of dysplasia and CIS observed in our patients with lung cancer and in the smoking volunteers are consistent with the findings in these earlier studies.
Our study suggests that fluorescence bronchoscopy, in conjunction with standard white-light bronchoscopy, may be very useful in the detection of synchronous and second primary tumors in patients with lung cancer. In high risk populations such as heavy smokers, fluorescence bronchoscopy may also be useful for localizing precancerous lesions and CIS. This technology, in combination with local treatments such as photodynamic therapy which can eradicate these lesions without loss ofnormal lung tissues, offers hope that the traditionally poor prognosis of lung cancer may be altered in a significant way.
